Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MDUFMA Adjustments Gain Dems’ Support As Congress Heads Toward Recess

This article was originally published in The Gray Sheet

Executive Summary

Sens. Edward Kennedy (D-Mass.) and Judd Gregg (R-N.H.) have reached consensus on the "Medical Device Technical Corrections Act" (S 1881), according to staffers

You may also be interested in...



Third Party Inspections Await Reconciliation of Technical Corrections Bills

Third-party inspection proponents are hoping that momentum from House passage of the Medical Device User Fee & Modernization Act technical corrections bill will propel enactment within the next few weeks

Third Party Inspections Await Reconciliation of Technical Corrections Bills

Third-party inspection proponents are hoping that momentum from House passage of the Medical Device User Fee & Modernization Act technical corrections bill will propel enactment within the next few weeks

Technical corrections clear Senate

"Medical Device Technical Corrections Act" (S 1881) passes Senate floor vote Nov. 25 by unanimous consent. Sponsored by Sen. Lamar Alexander (R-Tenn.), the bill represents a bipartisan consensus on third-party inspections (1"The Gray Sheet" Nov. 24, 2003, p. 17). The legislation includes an 18-month moratorium on implementation of Sec. 301 of MDUFMA requiring manufacturers to put their name on devices, giving more time for FDA and Congress to weigh potential changes (2"The Gray Sheet" Oct. 27, 2003, In Brief)...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT019367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel